Adjunctive radiofrequency ablation for the endoscopic treatment of ampullary lesions with intraductal extension (with video)

Authors
Alejandro L. Suarez, Gregory A. Coté, B. Joseph Elmunzer

Institution
Division of Gastroenterology & Hepatology, Medical University of South Carolina, Charleston, S.C. USA.

Background and study aims: Catheter-based radiofrequency ablation (RFA) delivered during endoscopic retrograde cholangiopancreatography (ERCP) may represent a viable treatment option for intraductal extension of ampullary neoplasms, however, clinical experience with this modality is limited. After ampullary resection, 4 patients with intraductal extension underwent adjunctive RFA of the distal bile duct. All patients received a temporary pancreatic stent to reduce the risk of pancreatitis, as well as a plastic biliary stent to prevent biliary obstruction. Three patients were treated for adenoma and 1 for adenoma with a focus of adenocarcinoma. During a short follow-up period, 3 patients experienced complete eradication of the target lesion, whereas the patient with a focus of adenocarcinoma had progression to overt invasive cancer. There were no immediate adverse events. One patient developed a post-RFA bile duct stricture, which has required additional endoscopic therapy. Catheter-based RFA of ampullary lesions that extend up the bile duct is technically feasible. Additional research is necessary to understand the risks and long-term benefits of this technique.

Introduction
Catheter-based radiofrequency ablation (RFA) delivered during endoscopic retrograde cholangiopancreatography (ERCP) has recently emerged as a possible therapeutic option within the bile duct. Intraductal extension of neoplasm remains an important challenge in the endoscopic eradication of complex ampullary lesions, and RFA may represent a viable treatment adjunct for this problem. Recently, the use of RFA at the ampulla and within the distal bile duct has been described. In the present study, we present 4 cases assessing the technical feasibility, safety, and treatment outcomes of RFA employed at the time of ERCP to treat ampullary lesions with intraductal extension.

Case Reports
The study was conducted at the Medical University of South Carolina (MUSC) from July 1, 2014 through October 1, 2015. After institutional review board approval, we retrospectively identified eligible adult subjects through the MUSC endoscopy report database (Endoworks, Olympus America, Center Valley, PA) by searching for reports that contained the keywords “radiofrequency ablation (RFA)” and “endoscopic retrograde cholangiopancreatography (ERCP).” We excluded patients who underwent RFA of a stricture not associated with an ampullary lesion. We collected relevant clinical, histologic, and endoscopic data on all eligible subjects. All procedures were performed by an experienced pancreaticobiliary endoscopist under general anesthesia using a side-viewing duodenoscope. Included patients had undergone histologic evaluation of their ampulla prior to treatment. Ampullary resection was performed either en bloc or in piecemeal fashion by delivering electro surgical current through a snare with or without prior submucosal lift. Intraductal extension of the lesion was assessed cholangiographically and/or visually. In some cases, a biliary sphincterotomy extension and papillary balloon dilation was performed to expose the inside of the terminal bile duct for assessment and therapy. Ablative therapy was delivered using a standard Argon Plasma Coagulation (APC) probe (ERBE USA Inc., Mariette, GA) at a flow rate of 1.0 L/min to 1.2 L/min and 30 to 40 maximum watts (W) and/or the Habib EndoHPB RFA bipolar cautery probe (EMcision United Kingdom, London, United Kingdom) at 10 W for 60 to 90 seconds, ex-
trapolating from manufacturer’s recommendations of 7 to 10W × 120 seconds [9]. Given the proximity to the pancreatic orifice and the benign nature of the target lesions, a shorter duration of treatment was chosen. In general, APC was reserved for treating exposed target tissue in the duodenum or very distal duct, whereas RFA was reserved for treating hidden or difficult to access tissue within the duct. All patients undergoing RFA received a temporary pancreatic stent (5 Fr, 2–5 cm) and rectal indomethacin to reduce the risk of post-ERCP pancreatitis (PEP), as well as a plastic endobiliary prostheses to prevent biliary obstruction and cholangitis.

Technical success was defined as the ability to successfully position the RFA probe across the biliary orifice and deliver thermal energy to the region of the papilla and terminal bile duct, resulting in coagulation of the visualized target areas. Clinical success was defined as endoscopic absence of polypoid or adenomatous-appearing tissue at the treatment site and histologic absence of neoplasm based on extensive follow-up biopsies from the papilla, pancreaticobiliary septum, biliary orifice, and distal bile duct. When the distal bile duct was not fully exposed by prior sphincterotomy, a pediatric biopsy forceps was introduced into the distal duct to acquire tissue. We intended to repeat RFA sessions until visual and histologic clearance was observed.

Patient demographics, procedure indications, and treatment outcomes are listed in Table 1. Four eligible patients were identified, all of whom were men with a mean age of 63 years (range 54–84). Three patients (75%) had a history of familial adenomatous polyposis (FAP). Three patients were treated for ampullary adenoma and 1 for ampullary adenoma with a focus of adenocarcinoma (he declined surgical evaluation).

Video 1 presents a synopsis of 2 representative cases. All RFA procedures were technically successful, resulting in a perceptible tissue effect (Fig. 3). RFA was performed immediately following endoscopic resection in 1 case and during a subsequent session in the remaining cases. The mean number of RFA sessions per patient was 1.5 (range 1–3). All patients were discharged uneventfully after the procedure without any immediate adverse events.
ment seems reasonable. If the pancreatic and biliary orifices are available, prophylactic pancreatic stent placement until additional data on the risk of post-ERCP pancreatitis in the context of benign ampullary disease in which patients do not typically undergo long-term stent placement, as is the case when RFA is performed for palliation of malignant strictures. Along these lines, until additional data are available, we have attempted to minimize RFA across the cystic duct takeoff to avoid thermal injury-related obstruction of the cystic duct, which has intentionally been induced by electrohydraulic lithotripsy to treat refractory bile leak.

In our series, RFA appears to have provided effective adjunctive therapy in all 4 cases of benign pathology but was ineffective in the setting of early adenocarcinoma, underscoring the concept that surgical resection remains first-line therapy for ampullary cancer (our patient declined surgery and chemoradiation). Despite the apparent effectiveness for benign lesions, it is important to consider that intrabiliary extension is often nodular in nature, leading to heterogeneous contact between the RFA probe and the target tissue; this may lead to incomplete therapy and/or an increased risk of buried neoplasm as is the concern when RFA is used to treat nodular Barrett’s esophagus. Moreover, it can be technically challenging to ensure circumferential contact of the probe and the target tissue within a dilated bile duct, even when luminal air is suctioned to induce collapse of the duct around the probe. In these cases, a balloon-based RFA device that flattens nodular tissue and maximizes treatment contact may be of value.

An additional consideration is that the proximal extent of neoplasm is often difficult to assess cholangiographically and the role of cholangioscopy to guide probe placement should be further explored. Prospective studies are necessary to evaluate these issues and determine the long-term effectiveness of this modality.

In summary, catheter-based RFA after endoscopic resection of ampullary lesions that extend up the bile duct is technically feasible. Concerns regarding injury to the pancreas and bile duct as well as incomplete treatment of nodular target tissue exist and will be addressed by additional clinical experience and research.

Competing interests: None

References
1 Dolak W, Schreiber F, Schweighofer H et al. Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. Surg Endosc 2014; 28: 854–860
2 Steel AW, Postgate AJ, Khorsandi S et al. Endoscopically applied radio-frequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointest Endosc 2011; 73: 149–153
3 Monga A, Gupta R, Ramchandani M et al. Endoscopic radiofrequency ablation of cholangiocarcinoma: new palliative treatment modality (with videos). Gastrointest Endosc 2011; 74: 935–937
4 Tal AO, Vermehren J, Friedrich-Rust M et al. Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. World J Gastrointest Endosc 2014; 6: 13–19
5 Bohnacker S, Setz U, Nguyen D et al. Endoscopic resection of benign tumors of the duodenal papilla without and with intraductal growth. Gastrointest Endosc 2005; 62: 551–560
6 Ridtitid W, Tan D, Schmidt SE et al. Endoscopic papillectomy: risk factors for incomplete resection and recurrence during long-term follow-up. Gastrointest Endosc 2014; 79: 289 – 296
7 Mehendiratta V, Desilets DJ. Use of radiofrequency ablation probe for eradication of residual adenoma after ampullectomy. Gastrointest Endosc 2015; 81: 1055 – 1056
8 Valente R, Urban O, Del Chiaro M et al. ERCP directed radio-frequency ablation (RFA) of an intra-pancreatic duct (PD) and intra-bile duct (BD) growing ampullary adenoma. A possible safe and mini invasive alternative to surgical treatment. Pancreatology 2015; 15: S98
9 Itoi T, Isayama H, Sofuni A et al. Evaluation of effects of a novel endoscopically applied radiofrequency ablation biliary catheter using an ex-vivo pig liver. J Hepatobiliary Pancreat Sci 2012; 19: 543 – 547
10 Catalano MF, Linder JD, Chak A et al. Endoscopic management of adenoma of the major duodenal papilla. Gastrointest Endosc 2004; 59: 225 – 232
11 Saleem A, Wang KK, Baron TH. Successful endoscopic treatment of intraductal extension of a villous adenoma with high-grade dysplasia, with 3-year follow-up. Gastrointest Endosc 2011; 74: 714 – 716
12 Kim JH, Moon JH, Choi HJ et al. Endoscopic snare papillectomy by using a balloon catheter for an unexposed ampullary adenoma with intraductal extension (with videos). Gastrointest Endosc 2009; 69: 1404 – 1406
13 Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009; 360: 2277 – 2288
14 Shahid H, Korenblit J, Kowalski T et al. Novel application of electrohydraulic lithotripsy probe in managing a refractory cystic duct bile leak. Gastrointest Endosc 2014; 80: 744 – 745